ADM and prostate cancer: Overexpression of AM has been observed in various cancers; the oncogenic effects of adrenomedullin (AM) and AM2 (intermedin) in numerous types of cancer, including breast, lung, pancreatic, and prostate cancer and gliomas, have been widely reported [6,16].